• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Sex difference in clinical and procedural outcomes in patients undergoing coronary atherectomy: a systematic review and meta-analysis
Conclusion In our analysis, women undergoing CA are at increased risk of mid-term mortality and procedure-related complications including stroke, coronary dissection, and major bleeding.
Source: Coronary Artery Disease - October 29, 2022 Category: Cardiology Tags: Original Research Source Type: research

Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Conclusions Shortening the DAPT regimen to 1 or 6 months did not increase the risk of MACE, and the 6-month DAPT regimen reduced the risk of major bleeding. However, the 3-month DAPT regimen increased the risk of ischemic stroke. Thus, shortened DAPT reduced the risk of MACE and bleeding, with a small absolute increase in ischemic strokes.
Source: Coronary Artery Disease - October 6, 2022 Category: Cardiology Tags: Reviews in Depth Source Type: research

White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial
Conclusion There was no association between baseline WBCc and 30-day or 5-year clinical outcomes after PCI or CABG. The absence of a clear incremental increase in events with increasing WBCc in the current analysis indicates that WBCc should not routinely be used as a prognostic marker or to guide revascularization decisions in patients with LMCAD.
Source: Coronary Artery Disease - December 9, 2021 Category: Cardiology Tags: PCI Source Type: research

Clinical features, sex differences and outcomes of myocardial infarction with nonobstructive coronary arteries: a registry analysis
Conclusion The incidence of MINOCA was 9.5%. Compared to OACD-MI, patients with MINOCA have less cardiac risk factors. In-hospital outcomes of patients diagnosed with MINOCA were better than OACD-MI.
Source: Coronary Artery Disease - December 23, 2020 Category: Cardiology Tags: Acute Coronary Syndromes Source Type: research

Temporal trends and predictors of time to coronary angiography following non-ST-elevation acute coronary syndrome in the USA
Conclusion Use of early CA has increased in the management of NSTEACS; however, there remain significant disparities in utilization of an early invasive approach in women, African Americans, admission day and older patients in the USA.
Source: Coronary Artery Disease - April 11, 2019 Category: Cardiology Tags: Acute Myocardial Infarction Source Type: research

Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis
Conclusion Among patients with an indication for oral anticoagulation after percutaneous coronary intervention, DT appears to be the optimal strategy.
Source: Coronary Artery Disease - February 2, 2019 Category: Cardiology Tags: Antiplatelet Therapy in PCI Source Type: research

Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials
Conclusion In patients who require chronic OAC therapy and undergo coronary stent placement, short-term TAT was associated with better efficacy and safety outcomes compared to long-term TAT.
Source: Coronary Artery Disease - February 2, 2019 Category: Cardiology Tags: Antiplatelet Therapy in PCI Source Type: research

Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis
Conclusion Dual therapy may be a reasonable alternative to triple therapy after PCI in patients with indication for chronic anticoagulation. However, further studies are needed to investigate efficacy of dual therapy, especially in the patients with higher ischemic risk, such as in ACS.
Source: Coronary Artery Disease - December 1, 2018 Category: Cardiology Tags: Anti-platelet therapy in CAD Source Type: research

Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
Conclusion In ‘real-life’ ACS undergoing PCI, diabetic patients have higher – although not significantly – MACE rate and no difference in bleeding events. This difference in MACE was significant among clopidogrel-treated patients, whereas when newer antiplatelet agents were used the negative impact of DM on ischemic events was eliminated.
Source: Coronary Artery Disease - January 1, 2018 Category: Cardiology Tags: Original Research Source Type: research

Atrial fibrillation, bleeding, and coronary intervention: current recommendations
The patient population with the need for oral anticoagulation to reduce stroke risk associated with atrial fibrillation (AF) and dual antiplatelet therapy to prevent stent thrombosis and myocardial infarction after percutaneous coronary intervention is increasing. However, patients treated with a triple therapy consisting of oral anticoagulation, aspirin, and a P2Y12 inhibitor have been demonstrated to be at high bleeding risk. The best combination of these agents and the duration of the different therapies are still uncertain. Recently, data on the safety of combinations including nonvitamin K antagonists have been publis...
Source: Coronary Artery Disease - November 2, 2017 Category: Cardiology Tags: Review in depth Source Type: research

Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition
Despite the use of therapies recommended in practice guidelines for secondary prevention in patients with atherosclerotic coronary artery disease, the residual risk for cardiovascular events remains high. Some of the residual risk is believed to result from incomplete platelet inhibition with current therapy. Vorapaxar is a first-in-class, novel antiplatelet agent that acts by antagonizing the PAR-1 receptor, inhibiting thrombin-mediated platelet activation. Vorapaxar was recently approved by the Food and Drug Administration for secondary prevention of cardiovascular events in patients with a history of myocardial infarcti...
Source: Coronary Artery Disease - September 30, 2016 Category: Cardiology Tags: Reviews in Depth Source Type: research

A regional pharmacoinvasive PCI strategy incorporating selected bleeding avoidance strategies
ConclusionBleeding and ischemia rates were similar between the PIT and primary PCI strategies in the setting of routine use of selected BAS; further study on a broader range of BAS including the radial approach may be warranted. Cardiac arrest and bailout glycoprotein IIb/IIIa inhibitor, but not PIT in conjunction with selected BAS, are independent predictors of bleeding risk in a regional ST-segment elevation myocardial infarction population.
Source: Coronary Artery Disease - December 10, 2014 Category: Cardiology Tags: Original Research Source Type: research

Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction
ConclusionThe benefits of SES in STEMI patients in terms of reducing MACCE faded over time. We found no safety concerns in terms of SES in the long term, with extremely low rates of very late stent thrombosis.
Source: Coronary Artery Disease - July 3, 2014 Category: Cardiology Tags: Original Research Source Type: research

Warfarin for stroke prevention following anterior ST-elevation myocardial infarction
ConclusionIschemic stroke was infrequent in the 6 months following anterior STEMI irrespective of VKA treatment status. The routine use of anticoagulation for prevention of stroke following anterior STEMI may not be warranted.
Source: Coronary Artery Disease - November 8, 2013 Category: Cardiology Tags: Original Research Source Type: research